title: Response by Fordyce et al to Letter Regarding Article, "On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF".
authors.affiliation: From Division of Cardiology, University of British Columbia, Vancouver, Canada (C.B.F.); and Duke Clinical Research Institute, Durham, NC (C.B.F., J.P.P., M.R.P.).
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Fordyce
authors.affiliation: From Division of Cardiology, University of British Columbia, Vancouver, Canada (C.B.F.); and Duke Clinical Research Institute, Durham, NC (C.B.F., J.P.P., M.R.P.).
authors.forename: Jonathan P
authors.initials: JP
authors.lastname: Piccini
authors.affiliation: From Division of Cardiology, University of British Columbia, Vancouver, Canada (C.B.F.); and Duke Clinical Research Institute, Durham, NC (C.B.F., J.P.P., M.R.P.).
authors.forename: Manesh R
authors.initials: MR
authors.lastname: Patel
mesh_terms: D000925:Anticoagulants; D001281:Atrial Fibrillation; D065427:Factor Xa Inhibitors; D006801:Humans; D000069552:Rivaroxaban; D020521:Stroke; D016896:Treatment Outcome; D014859:Warfarin
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D014859:Warfarin; D000069552:Rivaroxaban